Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRI of Epicardial Adipose Tissue Composition in HFpEF
NCT07178145Phase 4Recruiting
- Sponsor
- University of Virginia
- Start
- Nov 2025
- Primary completion
- Sep 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of semaglutide in heart failure with preserved ejection fraction (HFpEF) (3 arms), sponsored by University of Virginia. Primary endpoint: Epicardial adipose tissue fatty acid composition at 9 months. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT07178145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07178145.